Kunming Pharmaceutical Group 3.2 ferrous fumarate tablets for iron deficiency anemia

According to the public information released by the State Food and Drug Administration on April 29, the 3.2-class iron deficiency anemia drug of Kunming Pharmaceutical Co., Ltd., ferrous folic acid fumarate tablets, entered the site for inspection This means that the drug is expected to become the first imitation in China after passing the inspection of production environment and process Industry insiders said, "if it goes smoothly, it will be approved within this year." In China, the prevalence rates of iron deficiency anemia and iron deficiency (ID) pregnant women are 19.1% and 42.6% respectively, and even 33.8% and 51.6% in the third trimester, which exist in both urban and rural women At present, iron supplement is mainly used as the first-line drug to treat iron deficiency anemia, but research shows that the combination of ferrous folic acid is more conducive to the prevention and treatment of anemia in pregnant women According to the public information, there are not a few enterprises that develop fumarate ferrous folic acid compound preparation in China Since 2006, there have been eight enterprises approved for clinical application, including Jinan Bainuo Pharmaceutical Co., Ltd., Tianjin Kaiwen biology Co., Ltd and Nanjing Kesheng Pharmaceutical Co., Ltd.; only Kunming Pharmaceutical Co., Ltd and Nanjing Yiheng Pharmaceutical Co., Ltd have entered the application for production It is worth noting that Kunming Pharmaceutical has not obtained the clinical approval of the drug before, and insiders say that the company is likely to acquire the variety through acquisition.